https://www.selleckchem.com/products/rmc-4550.html
Seizure-free rates increased over time, at 14%, 19%, and 20% at 3, 6, and 12 months, respectively. The number of baseline anti-seizure medications (ASMs) and order of LCM introduction significantly impacted the likelihood of seizure remission during the 12-month follow-up period (p 0.05). During the entire period of LCM treatment, twenty-two children (30.5%) experienced at least one adverse reaction. This retrospective study of 72 pediatric patients with epilepsy in Uygur, China, showed that LCM therapy is safe and effective for e
Like
Comment
Share
